Callisto Pharmaceuticals Redirects Atiprimod Clinical Development to Treat Rheumatoid Arthritis
27 janv. 2009 08h00 HE
|
Synergy Pharmaceuticals
NEW YORK--Callisto Pharmaceuticals, Inc. (OTC BB: CLSP.OB) today announced that it is focusing further development of atiprimod on treatment of rheumatoid arthritis (RA). Atiprimod has demonstrated a...
Callisto Pharmaceuticals' Majority-Owned Subsidiary Synergy Pharmaceuticals Completes Phase I Trial of SP-304 in Volunteers
09 déc. 2008 13h25 HE
|
Synergy Pharmaceuticals
NEW YORK--Callisto Pharmaceuticals, Inc. (OTC BB:CLSP.OB), a developer of new drugs to treat cancer and gastrointestinal disorders, announced today that Synergy Pharmaceuticals (OTC BB: SGYP), its...
Synergy Pharmaceuticals Successfully Completes Phase I Trial of SP-304 in Volunteers
09 déc. 2008 09h16 HE
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the completion of the Phase I clinical trial of...
Dr. Mel Spigelman, Director of Synergy Pharmaceuticals, Appointed President and CEO of Global Alliance for TB Drug Development
15 oct. 2008 09h00 HE
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTC BB:SGYP.OB SGYP News) is pleased to congratulate Melvin K. Spigelman, M.D., a director of Synergy Pharmaceuticals, on his recent appointment as President...
Synergy Pharmaceuticals Announces Appointment of Dr. Mel Spigelman to Board of Directors
27 août 2008 19h02 HE
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTC BB:SGYP) is pleased to announce that on August 21, 2008, the Board of Directors of Synergy Pharmaceuticals, Inc. appointed Melvin K. Spigelman, M.D. as a...
Synergy Pharmaceuticals, Inc. Effects Name Change and Forward Stock Split
11 août 2008 09h59 HE
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTC BB: SGYP) (the "Company") (formerly Pawfect Foods, Inc.) is pleased to announce that it has changed its name to Synergy Pharmaceuticals, Inc. effective...